intermediate follow-up. Most patients undergoing mesh removal presented with pain in the presence of mesh erosion or exposure, but 28% reported pain in the absence of mesh exposure or erosion. This cohort also demonstrates coexisting psychiatric, immunosuppressive, and other chronic pain conditions that should be further investigated for impact on the development of mesh complications. Patients who do develop symptomatic pelvic floor mesh complications should be counseled on the option of surgical removal.
INTRODUCTION AND OBJECTIVES:
There is much data in the literature about the complications of vaginal mesh; however, there is much less addressing the clinical outcomes for patients who undergo vaginal mesh removal due to complications from their mesh. The objective of this study is to describe the clinical history leading up to as well as the outcomes after vaginal mesh removal surgery at an academic, tertiary care hospital.
METHODS: A retrospective study of patients who underwent vaginal mesh removal from 2008 to 2015. Demographics, clinical history, physical exam, pre-and post-operative symptoms, and number of re-operations were abstracted. Fisher 0 s exact test with significance at p<0.05 was used for comparative statistics.
RESULTS: Between February 2008 and November 2015, 84 patients underwent vaginal mesh removal at our hospital. The median time interval from initial mesh placement to removal was 58 months (range 0.4 to 154 months). Most patients (n¼61, 73%) had no prior history of mesh removal surgery. The most common pre-operative symptoms were vaginal pain (n¼52, 62%), dyspareunia (n¼ 46, 55%), and pelvic pain (n¼42, 50%). Intraoperative complications were infrequent with injury to the urethra, bladder, and bowel occurring in 1 patient each (n¼3, 4%). Of patients presenting for follow up within 4-6 weeks post-operatively, 45 (83%) were deemed better than before surgery. Pre-operative symptoms that improved by six weeks or greater following mesh removal surgery were mesh erosion (p<.0001), vaginal pain (p<.0001), vaginal bleeding (p¼0.0028), vaginal discharge (p¼0.0127), dyspareunia (p¼0.0024), and pelvic pain (p¼0.0005). There were no identifiable risk factors to predict which patients would have persistent post-operative symptoms or who would require more than one mesh removal surgery. After vaginal mesh removal, 29 patients (35%) required one or more re-operations with 3 being the highest number of reoperations.
CONCLUSIONS: Vaginal mesh removal surgery is safe and can alleviate many pre-operative symptoms. Some patients require more than one procedure and the risk factors for reoperations are unclear. Matteo Balzarro*, Emanuele Rubilotta, Antonio Benito Porcaro, Nicolò Trabacchin, Sarti Alessandra, Maria Angela Cerruto, Salvatore Siracusano, Walter Artibani, Verona, Italy INTRODUCTION AND OBJECTIVES: The aim of our study was to assess the long-term efficacy, the outcomes, and the complications in patients treated for pelvic organ prolapse (POP) with transvaginal anterior colporrhaphy alone (AC), AC and reinforcement by porcine Xenograft (Pelvisoftâ) (AC-P), and AC and reinforcement by polypropylene mesh (AC-M). Vol. 197, No. 4S, Supplement, Saturday, May 13, 2017 THE JOURNAL OF UROLOGY â e357
